latest news in companies
Fagron Bolsters North American Presence with $41.5 Million Strategic Acquisition
Rotterdam, Monday, 12 January 2026.
Fagron cements its North American expansion by finalizing the $41.5 million acquisition of University Compounding Pharmacy, immediately adding $25 million in annual revenue to its personalized medicine portfolio.
Sanofi Wins First EU Approval for Therapy Delaying Type 1 Diabetes Onset
Paris, Monday, 12 January 2026.
On January 12, 2026, Sanofi achieved a significant regulatory milestone as the European Commission approved Teizeild (teplizumab), marking the European Union’s first disease-modifying therapy authorized to delay the onset of stage 3 type 1 diabetes. This approval, applicable to adults and children aged eight and older with stage 2 diabetes, is grounded in compelling data from the TN-10 Phase 2 study. The trial demonstrated that Teizeild could delay disease progression by a median of two years, a critical timeframe for patients and families. Analytically, the results were robust: 57% of patients treated with the therapy remained in stage 2, compared to only 28% in the placebo group. This authorization not only strengthens Sanofi’s immunology portfolio but represents a paradigm shift in diabetes management, moving from reactive symptomatic treatment to proactive preventative intervention for high-risk individuals across the European market.
Trump Signals Intent to Exclude ExxonMobil from Venezuela Following CEO's Skepticism
Washington D.C., Monday, 12 January 2026.
Labeling ExxonMobil’s caution as “playing too cute,” President Trump signaled plans to bar the energy giant from Venezuela after CEO Darren Woods deemed the current legal framework “uninvestable.”
